EndoTODAY
| EndoATLAS
| OPD
Parasite
| Eso
| Sto
| Cancer
| ESD
| Boxim | DEX
| ÀÏÁ¤
Home
| Recent
| Blog
| Links
★ YouTube ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò
[2015³â JDDW µ¿°æ]
ÀϺ»¼Òȱ⿬°üÇÐȸ(JDDW)¿¡ ESD hands-on course °»ç·Î ÃÊ´ëµÇ¾î µ¿°æÀ» ã¾Ò½À´Ï´Ù. ÇÏ·ç ÀÏÂï µµÂøÇÏ¿© JDDW ½ÉÆ÷Áö¾ö¿¡¼ ½Ã°£À» º¸³Â½À´Ï´Ù.
Çö¶õÇÑ ÀϺ»ÀÇ ÇÐȸ Æ÷½ºÅ͵é
1. Ç︮ÄÚ¹ÚÅÍ
±Ý¿äÀÏ ¿ÀÀü 9½Ã ¾Æ»çÄ« ¼±»ýÀÌ 1¹ø¹æ(°¡Àå Å« ¹æ)¿¡¼ 'À§¾Ï°ü·Ã »ç¸ÁÀ» 2020³â±îÁö Àý¹ÝÀ¸·Î ÁÙÀÌ´Â Àü·«'¿¡ ´ëÇÏ¿© À̾߱âÇß½À´Ï´Ù.
°ÀÇ ¸¶Áö¸· ½½¶óÀ̵åÀÔ´Ï´Ù. ÇÛ¸®ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á¿Í screeningÀ¸·Î À§¾Ï »ç¸ÁÀÚ¸¦ ÇöÀçÀÇ 5¸¸¸í¿¡¼ Àý¹Ý ÀÌÇÏ·Î ÁÙÀÏ ¼ö ÀÖ´Ù´Â ÁÖÀåÀ̾ú½À´Ï´Ù.
Ä«¿Í»çÅ° ´ëÇÐÀÇ Ä«¸¶´Ù ¼±»ýÀÌ Ç︮ÄÚ¹ÚÅÍ¿Í À§¿° ÄìÅä ºÐ·ù¿¡ ´ëÇÏ¿© ¹ßÇ¥ÇÏ¿´½À´Ï´Ù.
Duffuse redness´Â Ç︮ÄÚ¹ÚÅÍ ÇöÀç°¨¿°, Map-like redness´Â Ç︮ÄÚ¹ÚÅÍ °ú°Å°¨¿°ÀÇ Æ¯Â¡À̶ó°í ÇÕ´Ï´Ù. ÀÌ µÑÀ» ¾ó¸¶³ª Á¤È®È÷ ±¸ºÐÇÒ ¼ö ÀÖÀ»Áö Àǹ®ÀÔ´Ï´Ù. ±×·±µ¥ ÀϺ»ÀεéÀº ¿Ö ³»½Ã°æ ¼Ò°ßÀ¸·Î Ç︮ÄÚ¹ÚÅÍ °¨¿°¿©ºÎ¸¦ ³ª´©·Á°í ½ÃµµÇÏ´Â °ÍÀϱî¿ä? ±×³É °Ë»çÇعö¸®¸é °£´ÜÇѵ¥ ¸»ÀÔ´Ï´Ù. ´«¿¡ º¸ÀÌ´Â ¿©·¯ ¼Ò°ßÀ» ¾î¶»°Ôµç ¼³¸íÇغ¸·Á´Â ½Ãµµ·Î »ý°¢µÇ¾ú½À´Ï´Ù.
2. ·±Ãµ - Ç︮ÄÚ¹ÚÅÍ Ä¡·á
·±Ãµ ¼¼¼ÇÀº °¢ ¹æ¸¶´Ù ¿·È´Âµ¥ Àú´Â ¿µ¾î °ÀÇ°¡ ¿¸®´Â 1¹ø ¹æ¿¡¼ ±×¶óÇÔ ¼±»ý°ú ¾Æ»çÄ« ¼±»ýÀÇ °ÀǸ¦ µé¾ú½À´Ï´Ù. ±×¶óÇÔ °ÀÇ Áß ÀϺΠ³»¿ëÀÔ´Ï´Ù.
- Áß±¹ ¼Ò¾Æ¿¡¼ Hp vacciation Lancet ³í¹®ÀÌ ÃÖ±ÙÀÇ Áß¿äÇÑ miilestoneÀÔ´Ï´Ù (Zeng M. Lancet 2015).
- ÀúÇ×¼ºÀÌ ÈçÇÑ Áö¿ª¿¡¼´Â clarithromycin-based triple therapyÀ» ¾²Áö ¸»¾Æ¾ß ÇÕ´Ï´Ù.
- Population ´ë»ó Ä¡·á¹æħÀ» Á¤ÇÒ ¶§¿¡´Â local resistance patternÀ» °í·ÁÇؾßÇÏ°í Àû¾îµµ 90%ÀÌ»óÀº µÇ¾î¾ßÇÑ´Ù°í ÁÖÀåÇß½À´Ï´Ù.
- ¹Ì±¹¿¡¼´Â clarithromycin, metronodazole dual resistance´Â 5% ÀÌÇÏÀÔ´Ï´Ù.
- ÀÚ½ÅÀº ¹Ì±¹¿¡¼ 14 day cocomittent therapy ȤÀº 14 day quadruple therapy¸¦ ±ÇÇÕ´Ï´Ù.
- Vonoprazone (potassium channel blocker, P-cap)À» ¾²¸é PPI º¸´Ù È¿°ú°¡ ÁÁ½À´Ï´Ù. ¾ÕÀ¸·Î Vonoprazone + Amoxicillin dual therapy°¡ Ç¥ÁØÀÌ µÉ °ÍÀ¸·Î Àü¸ÁÇß½À´Ï´Ù.
3. ¹Ù·¿½Äµµ¾Ï
¿ÀÈÄ¿¡´Â ¹Ù·¿ ½ÉÆ÷Áö¾öÀÌ ÀÖ¾ú½À´Ï´Ù.
¸ÕÀú Kansas ´ëÇÐÀÇ Sharma ¹Ú»ç °ÀÇ Áß ÀϺÎÀÔ´Ï´Ù.
- ½Äµµ¼±¾ÏÀº 1980³âºÎÅÍ ±Þ°ÝÈ÷ Áõ°¡ÇÏ´Ù°¡ 2000³â´ë µé¾î Áõ°¡¼¼°¡ ´Ù¼Ò ÁÙ¾ú½À´Ï´Ù.
- ¹Ì±¹Àο¡¼´Â pallisading vesselÀÌ ¾È º¸ÀÌ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.
- ¹Ù·¿½ÄµµÀÇ ±æÀÌ´Â ½Ã°£ÀÌ Áö³ªµµ stable ÇÕ´Ï´Ù. Age group¿¡ µû¶ó ´Ù¸£Áö ¾Ê½À´Ï´Ù. µû¶ó¼ ÀþÀº ³ªÀÌÀÇ ±æÀÌ°¡ À¯ÁöµÈ´Ù°í »ý°¢µË´Ï´Ù.
- Non-dysplastic Barrett ÀÇ ¾Ï¹ß»ý·üÀº ÃÖ±Ù ¿¬±¸¿¡¼´Â ³·°Ô º¸°íµÇ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù ¿¬±¸¿¡¼ population study¿Í prospective studyÀÇ °á°ú°¡ Ãʱ⿡´Â ´Þ¶ú½À´Ï´Ù.
- CAPRIS database ¿¬±¸¿¡¼ ¾¾¾ÖƲ ÇÁ·ÎÅäÄÝÀ» ÁöÅ°´Â °æ¿ì, Áï adherence rate´Â 51%¿´½À´Ï´Ù.
- BIT (Barrett inspection time)ÀÌ ±æ¾îÁö¸é neoplastic lesionÀ» ãÀ» È®·üÀÌ ³ô¾ÆÁý´Ï´Ù. 2013
ÀÌ´Â EGD¸¦ 7ºÐ ÀÌ»ó ÇßÀ» ¶§ À§ Á¾¾çÀ» ¹ß°ßÇÒ È®·üÀÌ ³ô¾ÆÁø´Ù´Â ¿¬±¸ °á°ú¿Í ºñ½ÁÇÕ´Ï´Ù.
- BING classificationÀÌ Á¦¾ÈµÇ¾ú½À´Ï´Ù.
- WATS cytology¸¦ ¼Ò°³Çß½À´Ï´Ù. Transepithelial sampling + ÄÄÇ»ÅÍ·Î ½ºÅ©¸®´×À» ÇÏ¿© °¡Àå ºñÁ¤»óÀûÀÎ ºÎºÐÀ» º´¸®Àǻ翡°Ô º¸¿©ÁÖ´Â ¹æ¹ýÀÔ´Ï´Ù.
- Barrett associated dysplasia/cancer¿¡¼ dysplastia/cancer¸¦ ³»½Ã°æÀ¸·Î Á¦°ÅÇÑ ÈÄ¿¡´Â ¸ðµç ¹Ù·¿ Á¡¸·À» Á¦°ÅÇÏ´Â °ÍÀÌ ¿øÄ¢ÀÔ´Ï´Ù. Sharma ¹Ú»ç´Â quality indicator¸¦ µé¸ÔÀ̸ç ÀÌ ºÎºÐÀ» ¸Å¿ì °Á¶Çß½À´Ï´Ù. ¹Ì±¹¿¡¼´Â EMR-C ÈÄ RF ablationÇÏ´Â °ÍÀÌ Ç¥ÁØÀ̶ó°í ÇÕ´Ï´Ù. (Âü°í·Î ÀϺ»À̳ª ¿ì¸®³ª¶ó¿¡¼´Â RF ablationÀÌ µµÀÔµÇÁö ¾Ê¾Ò±â ¶§¹®¿¡ careful observationÀÌ Ç¥ÁØÀÔ´Ï´Ù.)
- ESD °¡ multiple piecemeal resection º¸´Ù ÁÁÀ»Áö ÀÚ·á´Â ºÎÁ·ÇÕ´Ï´Ù. ¹Ù·¿¾ÏÀº field defectÀ̹ǷΠlateral marginÀÌ ´ú Áß¿äÇϱ⠶§¹®ÀÔ´Ï´Ù.
- Buried Barrett mucosa¾Ö ´ëÇÑ ¿ì·Á°¡ ÀÖ¾î¼ ³»½Ã°æÀ¸·Î Ä¡·áÇÑ È¯ÀÚÀÇ OCT ¸¦ ÀÌ¿ëÇÑ surveillance ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.
Takubo ¼±»ýÀº ¹Ù·¿½Äµµ¾ÏÀÇ º´¸®¿¡ ´ëÇÏ¿© ¼³¸íÇÏ¿´½À´Ï´Ù. ¹Ù·¿ÀÇ º´¸®ÇÐÀû landmark´Â ¾Æ·¡ÀÇ 4°³ ÀÔ´Ï´Ù.
- Esophageal gland proper
- Squamous island
- Palisading vessel
- Double muscularis mucosa
WHO bluebookÀÇ dysplasia »çÁøÀº ÀϺ»¿¡¼´Â ¾ÏÀ¸·Î °£Áֵȴٰí ÇÕ´Ï´Ù. Á¡¸·¿¡ ±¹ÇÑµÈ ¹Ù·¿½Äµµ¾ÏÀÇ 2%¿¡¼ ¸²ÇÁÀý ÀüÀÌ°¡ ÀÖ´Ù°í ÇÕ´Ï´Ù. ÀϺ»¿¡ ´ÜºÐÀý ȤÀº ÃʴܺÐÀý ¹Ù·¿°ú °ü·ÃµÈ ¾ÏÀÌ ¸¹Àº °ÍÀº Ȥ½Ã proximal gastric cancer ȤÀº cardia cancer¸¦ Barrett ¾ÏÀ¸·ÎºÐ·ùÇÑ °Í ¾Æ´Ñ°¡ÇÏ´Â Sharma ¹Ú»çÀÇ comment °¡ ÀÖ¾ú½À´Ï´Ù. ÀÌ¿Í ºñ½ÁÇÑ À̽´´Â ¿ì¸®³ª¶ó¿¡µµ ÀÖ½À´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼ cardia cancer·Î ºÐ·ùµÈ ¾ÏÀÇ ÀϺδ ÀϺ» ±âÁØÀ¸·Î´Â Barrett adenocarcinoma ÀÏ °Í °°½À´Ï´Ù.
ÀϺ»ÀÇ ¿©·¯ ¼¾ÅÍ¿¡¼ ¹Ù·¿½Äµµ¾Ï ESD ¼ºÀûÀ» ¹ßÇ¥Çß½À´Ï´Ù.
- SM invasionÀÖ´Â °æ¿ì ¼ö¼úÀ» º¸³Ä´Â ±âÁØ¿¡ ´ëÇÑ ³í¶õÀÌ ÀÖ¾ú½À´Ï´Ù. ´Ù¼öÀÇ ÀϺ»ÀÎÀº 200um¸¦ ±âÁØÀ¸·Î Á¦½ÃÇßÁö¸¸ Oyama ¼±»ý´ÔÀº 500um°¡ ÁÁ°Ú´Ù´Â ÀÇ°ßÀ» ³ÂÀ¸¸ç, È£ÁÖÀÇ SinghÀº SM invasionÀÌ ÀÖÀ¸¸é ¸ðµÎ ¼ö¼úÀ» º¸³»ÀÚ°í Çß½À´Ï´Ù.
- ÇùÂøÀ» ¿¹¹æÇϱâ À§ÇÑ ÀüÁeµµ ³íÀǵǾú´Âµ¥ Oyama ¼±»ýÀº steroid injection, ƯÈ÷ repeated planned balloon dilatation + steroid injectionÀ» Á¦½ÃÇß½À´Ï´Ù.
4. Æ÷½ºÅÍ ¹ßÇ¥
Æ÷½ºÅÍ ¹ßÇ¥°¡ Æ÷½ºÅÍ°¡ ¾Æ´Ñ ÆÄ¿öÆ÷ÀÎÆ® ¹ßÇ¥¿´½À´Ï´Ù. 24°³ÀÇ cell¿¡¼ °¢ÀÚ ±¸¿¬¹ßÇ¥ÇÏ´Â Çü½ÄÀε¥ ¿ì¸®µµ Çغ¼¸¸ÇÏ´Ù°í »ý°¢Çß½À´Ï´Ù.
5. ESD hands-on training
ÀϺ»°ú Çѱ¹ÀÇ ¿©·¯ ¼±»ý´Ô²²¼ ESD hands-on training¿¡ tutor·Î Âü¼®ÇÏ¿´½À´Ï´Ù. Àú¿Í Tatsuya Mikami (Hirosaki University) ÆÀÀÇ trainee´Â Dr. Hu (ŸÀÌ¿Ï), Anwar H. Abbasi (ÆÄÅ°½ºÅº), Aleksei Epshtein (·¯½Ã¾Æ)¿´½À´Ï´Ù.
¿ÀÀü¹Ý
¿ÀÈĹÝ
Àü³²´ë ÀÌ¿Ï½Ä ±³¼ö´Ô°ú ÀÎÁ¦´ë ±èÁöÇö ±³¼ö´ÔÀÇ hands-on training tutoring
ÀϺ» Johnson & JohnsonÀÇ Yahuhisa Abe ¾¾°¡ ¸¸µç ESD training module (Âü°í: 2016³â JSGE¿¡¼ È®ÀÎÇÑ ¹Ù Abe¾¾´Â Boston ScientificÀ¸·Î ¿Å°å°í ±×°÷¿¡¼ animal modelÀ» °è¼Ó °³¹ßÇÏ°í ÀÖÀ½)
(µÞÁÙ) Katsuhiro Mabe (Hokkaido U), M. Fujushiro, ±èÁöÇö, À̿ϽÄ, (¾ÕÁÙ) ÀÌÁØÇà, T. Gotoda, Á¤ÈÆ¿ë, ¹ÚÁ¾Àç
[Âü°í ÀÚ·á]
1) ÀϺ» ÇÐȸ
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà